252 related articles for article (PubMed ID: 34284746)
1. Correlation between vascular endothelial growth factor pathway and immune microenvironment in head and neck squamous cell carcinoma.
Zhu C; Gu L; Liu Z; Li J; Yao M; Fang C
BMC Cancer; 2021 Jul; 21(1):836. PubMed ID: 34284746
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma.
Yao Y; Yan Z; Lian S; Wei L; Zhou C; Feng D; Zhang Y; Yang J; Li M; Chen Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32719094
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of immune cell infiltration and significant genes in head and neck squamous cell carcinoma.
Zhang S; Zhang W; Zhang J
Oral Oncol; 2022 Mar; 126():105755. PubMed ID: 35144208
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor receptor-2 and its association with tumor immune regulatory gene expression in hepatocellular carcinoma.
Liu ZL; Zhu LL; Liu JH; Pu ZY; Ruan ZP; Chen J
Aging (Albany NY); 2020 Nov; 12(24):25172-25188. PubMed ID: 33223512
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome analysis reveals the link between lncRNA-mRNA co-expression network and tumor immune microenvironment and overall survival in head and neck squamous cell carcinoma.
Zhong Z; Hong M; Chen X; Xi Y; Xu Y; Kong D; Deng J; Li Y; Hu R; Sun C; Liang J
BMC Med Genomics; 2020 Mar; 13(1):57. PubMed ID: 32228580
[TBL] [Abstract][Full Text] [Related]
6. Constructing heterogeneous single-cell landscape and identifying microenvironment molecular characteristics of primary and lymphatic metastatic head and neck squamous cell carcinoma.
Zhang J; Liu Y; Xia L; Zhen J; Gao J; Atsushi T
Comput Biol Med; 2023 Oct; 165():107459. PubMed ID: 37713790
[TBL] [Abstract][Full Text] [Related]
7. Subtyping of head and neck squamous cell cancers based on immune signatures.
Song D; Lyu H; Feng Q; Luo J; Li L; Wang X
Int Immunopharmacol; 2021 Oct; 99():108007. PubMed ID: 34332341
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the immune cell function landscape in head and neck squamous carcinoma to assist in prognosis prediction and immunotherapy.
Wang W; Zhang Z; Li W; Wei D; Xu J; Qian Y; Cao S; Lei D
Aging (Albany NY); 2023 Nov; 15(21):12588-12617. PubMed ID: 37955651
[TBL] [Abstract][Full Text] [Related]
10. The exploration of new therapeutic targets for HPV-negative head and neck squamous cell cancer through the construction of a ceRNA network and immune microenvironment analysis.
Wang Z; Liu T; Li G; Cao Z
J Cell Biochem; 2020 Jun; 121(5-6):3426-3437. PubMed ID: 31898341
[TBL] [Abstract][Full Text] [Related]
11. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma.
Shen A; Ye Y; Chen F; Xu Y; Zhang Z; Zhao Q; Zeng ZL
Front Immunol; 2022; 13():969034. PubMed ID: 36466881
[TBL] [Abstract][Full Text] [Related]
12. Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma.
Zhu C; Li J; Yao M; Fang C
BMC Oral Health; 2021 Oct; 21(1):506. PubMed ID: 34625078
[TBL] [Abstract][Full Text] [Related]
13. A Metabolism-Related Gene Prognostic Index Bridging Metabolic Signatures and Antitumor Immune Cycling in Head and Neck Squamous Cell Carcinoma.
Du K; Zou J; Wang B; Liu C; Khan M; Xie T; Huang X; Shen P; Tian Y; Yuan Y
Front Immunol; 2022; 13():857934. PubMed ID: 35844514
[TBL] [Abstract][Full Text] [Related]
14. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
15. PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma.
Wang L; Chen K; Weng S; Xu H; Ren Y; Cheng Q; Luo P; Zhang J; Liu Z; Han X
World J Surg Oncol; 2023 Mar; 21(1):72. PubMed ID: 36864522
[TBL] [Abstract][Full Text] [Related]
16. Dickkopf-1 is an immune infiltration-related prognostic biomarker of head and neck squamous cell carcinoma.
Zhao C; Liu L; He Q; Li Y; Feng J; Chen Y; Li Y; Xu X; Zhu S; Ye Y; Wen Y; Zeng Z; Zhou D; Jin F
Aging (Albany NY); 2024 Feb; 16(4):3837-3855. PubMed ID: 38376441
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma.
Mei Z; Huang J; Qiao B; Lam AK
Int J Oral Sci; 2020 May; 12(1):16. PubMed ID: 32461587
[TBL] [Abstract][Full Text] [Related]
19. Mast cell marker gene signature in head and neck squamous cell carcinoma.
Cai Z; Tang B; Chen L; Lei W
BMC Cancer; 2022 May; 22(1):577. PubMed ID: 35610596
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: A gene expression-based study.
Zhang L; Li B; Peng Y; Wu F; Li Q; Lin Z; Xie S; Xiao L; Lin X; Ou Z; Cai T; Rong H; Fan S; Li J
Oral Oncol; 2020 Nov; 110():104943. PubMed ID: 32919362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]